Edition: United States  
One News Page
“Probably the fastest-access news portal in the world”
> >

AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.

GlobeNewswire Friday, 13 October 2017 ()
"We very much look forward to this new collaboration with the England based Pathway Diagnostics for the distribution of our TK 210 ELISA test", states Jan Stålemark, AroCell CEO. "Pathway Diagnostics Ltd is a leading supplier of specialist clinical and research diagnostics in the UK and was established in 1998 to provide high quality in-vitro diagnostic products and instrumentation to clinical, research and industrial laboratories mainly in the UK and Ireland. Pathway Diagnostics are highly focused on the needs of their customers and in providing the highest quality products and service and therefore we consider them as a perfect match for our TK 210 ELISA test."

The TK 210 ELISA test will be commercially available immediately through Pathway Diagnostics in the UK and Irish market.

* For additional information:
* Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 08:50 CET on 13 October 2017.

* About AroCell
* AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure (Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provide valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during  monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see  www.arocell.com . Redeye AB is AroCell's Certified Adviser.

Press Release Distribution UK20171011_final
--------------------This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: AroCell AB via GlobeNewswire

HUG#2141700
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

You Might Like


Other recent news in Press Releases

Barrett-Jackson Raises $1 Million for LAS VEGAS First Responders Through the Injured Police Officers FundKubota Officially Announces Plans for $87 Million Expansion in Kansas to Create a New Logistics Hub, Add a Fifth Division and Midwest Sales OFFICE
Mid-2017 Report for CALIFORNIA Employees – What You Should Know About the Equal Pay Act, Drugs in the Workplace, and Transgender ProtectionsRedJade Announces Sensory SOFTWARE Updates Focused on Recruiting
Kevin Rowe Selected Among America's Top 100 High Stakes Litigators® in ARIZONAWilco Announces Tim RAMSEY as New CEO

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+